First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
2005 ◽
Vol 173
(4S)
◽
pp. 413-413
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):